title: Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation.
abstract: Forty-three patients received etoposide, cyclophosphamide, and fractionated total body irradiation before allogeneic marrow transplantation. Fifteen patients had chronic myelogenous leukemia in chronic phase or acute leukemia in first remission (standard risk) and twenty-eight patients with more advanced disease (high risk). All patients received etoposide 1,500 mg/m2 intravenously on day -8, cyclophosphamide 60 mg/kg/day intravenously on days -7 and -6, and total body irradiation at 170 cGy twice a day on days -3, -2, and -1. During the first 100 days 12 high risk patients (43%) died from causes unrelated to relapse while none of the standard risk patients died. Renal and hepatic dysfunction were also significantly increased during the first 14 days in the high risk group. The addition of 1,500 mg/m2 of etoposide to the cyclophosphamide and total body irradiation was well tolerated for patients with standard risk. However, the regimen was poorly tolerated with high mortality in patients with more advanced disease.
authors.affiliation: Ottawa Regional Cancer Center, Ontario, Canada.
authors.forename: J C
authors.initials: JC
authors.lastname: Yau
authors.forename: C F
authors.initials: CF
authors.lastname: LeMaistre
authors.forename: B S
authors.initials: BS
authors.lastname: Andersson
authors.forename: S D
authors.initials: SD
authors.lastname: Huan
authors.forename: R O
authors.initials: RO
authors.lastname: Wallerstein
authors.forename: S Y
authors.initials: SY
authors.lastname: Woo
authors.forename: G
authors.initials: G
authors.lastname: Spitzer
authors.forename: J A
authors.initials: JA
authors.lastname: Spinolo
authors.forename: V
authors.initials: V
authors.lastname: Spencer
authors.forename: L J
authors.initials: LJ
authors.lastname: Brunner
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007938:Leukemia / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D002330:Carmustine